These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 27799201

  • 21. In vivo efficacy of doripenem (DRPM) against Pseudomonas aeruginosa in murine chronic respiratory tract infection model.
    Araki N, Yanagihara K, Morinaga Y, Yamada K, Yamada Y, Kohno S, Kamihira S.
    J Infect Chemother; 2011 Jun; 17(3):318-21. PubMed ID: 20972597
    [Abstract] [Full Text] [Related]

  • 22. Characterization of Acinetobacter baumannii and meropenem-resistant Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-2009 study.
    McCracken M, Mataseje LF, Loo V, Walkty A, Adam HJ, Hoban DJ, Zhanel GG, Mulvey MR, Canadian Antimicrobial Resistance Alliance (CARA).
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):335-41. PubMed ID: 21353962
    [Abstract] [Full Text] [Related]

  • 23. Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model.
    Kidd JM, Abdelraouf K, Nicolau DP.
    J Antimicrob Chemother; 2020 Jan 01; 75(1):149-155. PubMed ID: 31641765
    [Abstract] [Full Text] [Related]

  • 24. Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.
    Rees VE, Yadav R, Rogers KE, Bulitta JB, Wirth V, Oliver A, Boyce JD, Peleg AY, Nation RL, Landersdorfer CB.
    Antimicrob Agents Chemother; 2018 Nov 01; 62(11):. PubMed ID: 30104278
    [Abstract] [Full Text] [Related]

  • 25. Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
    Lin YW, Zhou Q, Onufrak NJ, Wirth V, Chen K, Wang J, Forrest A, Chan HK, Li J.
    Antimicrob Agents Chemother; 2017 Aug 01; 61(8):. PubMed ID: 28559256
    [Abstract] [Full Text] [Related]

  • 26. Nebulized Amikacin and Fosfomycin for Severe Pseudomonas aeruginosa Pneumonia: An Experimental Study.
    Li Bassi G, Motos A, Fernandez-Barat L, Aguilera Xiol E, Chiurazzi C, Senussi T, Saco MA, Fuster C, Carbonara M, Bobi J, Amaro R, De Rosa F, Comaru T, Yang H, Ranzani OT, Marti JD, Rinaudo M, Comino Trinidad O, Rigol M, Bringué J, Ramirez J, Nicolau DP, Pelosi P, Antonelli M, Blasi F, Artigas A, Montgomery AB, Torres A.
    Crit Care Med; 2019 Jun 01; 47(6):e470-e477. PubMed ID: 30882478
    [Abstract] [Full Text] [Related]

  • 27. Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs.
    Kristoffersson AN, David-Pierson P, Parrott NJ, Kuhlmann O, Lave T, Friberg LE, Nielsen EI.
    Pharm Res; 2016 May 01; 33(5):1115-25. PubMed ID: 26786016
    [Abstract] [Full Text] [Related]

  • 28. Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem.
    So W, Crandon JL, Hamada Y, Nicolau DP.
    J Antimicrob Chemother; 2016 Feb 01; 71(2):428-37. PubMed ID: 26559690
    [Abstract] [Full Text] [Related]

  • 29. Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model.
    He J, Abdelraouf K, Ledesma KR, Chow DS, Tam VH.
    Int J Antimicrob Agents; 2013 Dec 01; 42(6):559-64. PubMed ID: 24016799
    [Abstract] [Full Text] [Related]

  • 30. Bacterial killing is enhanced by exogenous administration of lysozyme in the lungs.
    Epaud R, Delestrain C, Weaver TE, Akinbi HT.
    Respir Med Res; 2019 Nov 01; 76():22-27. PubMed ID: 31505323
    [Abstract] [Full Text] [Related]

  • 31. Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis.
    Miyazaki S.
    J Infect Chemother; 2004 Apr 01; 10(2):135. PubMed ID: 15160313
    [No Abstract] [Full Text] [Related]

  • 32. Efficacy and safety of meropenem (3 g daily) in Japanese patients with refractory respiratory infections.
    Kawanami T, Mukae H, Noguchi S, Yamasaki K, Akata K, Ishimoto H, Matsumoto K, Morita K, Yatera K.
    J Infect Chemother; 2014 Dec 01; 20(12):768-73. PubMed ID: 25193038
    [Abstract] [Full Text] [Related]

  • 33. Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model.
    Mohamed AF, Kristoffersson AN, Karvanen M, Nielsen EI, Cars O, Friberg LE.
    J Antimicrob Chemother; 2016 May 01; 71(5):1279-90. PubMed ID: 26850719
    [Abstract] [Full Text] [Related]

  • 34. In vivo dynamics of carbapenem-resistant Pseudomonas aeruginosa selection after suboptimal dosing.
    Tam VH, Ledesma KR, Schilling AN, Lim TP, Yuan Z, Ghose R, Lewis RE.
    Diagn Microbiol Infect Dis; 2009 Aug 01; 64(4):427-33. PubMed ID: 19631096
    [Abstract] [Full Text] [Related]

  • 35. [Bactericidal effect of levofloxacin injection in combination with meropenem against Pseudomonas aeruginosa using an in vitro simulation model with a hollow fiber system].
    Uoyama S, Kanda H, Yoshida K, Hoshino K.
    Jpn J Antibiot; 2012 Dec 01; 65(6):355-63. PubMed ID: 23593732
    [Abstract] [Full Text] [Related]

  • 36. Molecular pharmacodynamics of meropenem for nosocomial pneumonia caused by Pseudomonas aeruginosa.
    Farrington N, Dubey V, Johnson A, Horner I, Stevenson A, Unsworth J, Jimenez-Valverde A, Schwartz J, Das S, Hope W, Darlow CA.
    mBio; 2024 Feb 14; 15(2):e0316523. PubMed ID: 38236031
    [Abstract] [Full Text] [Related]

  • 37. Pharmacokinetics and pharmacodynamics of meropenem in children with severe infection.
    Kongthavonsakul K, Lucksiri A, Eakanunkul S, Roongjang S, Issaranggoon Na Ayuthaya S, Oberdorfer P.
    Int J Antimicrob Agents; 2016 Aug 14; 48(2):151-7. PubMed ID: 27345269
    [Abstract] [Full Text] [Related]

  • 38. Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program.
    Turner PJ.
    Diagn Microbiol Infect Dis; 2006 Nov 14; 56(3):341-4. PubMed ID: 17049798
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and pharmacokinetics of ME1100, a novel optimized formulation of arbekacin for inhalation, compared with amikacin in a murine model of ventilator-associated pneumonia caused by Pseudomonas aeruginosa.
    Kaku N, Morinaga Y, Takeda K, Kosai K, Uno N, Hasegawa H, Miyazaki T, Izumikawa K, Mukae H, Yanagihara K.
    J Antimicrob Chemother; 2017 Apr 01; 72(4):1123-1128. PubMed ID: 27999047
    [Abstract] [Full Text] [Related]

  • 40. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy.
    Riou M, Carbonnelle S, Avrain L, Mesaros N, Pirnay JP, Bilocq F, De Vos D, Simon A, Piérard D, Jacobs F, Dediste A, Tulkens PM, Van Bambeke F, Glupczynski Y.
    Int J Antimicrob Agents; 2010 Dec 01; 36(6):513-22. PubMed ID: 20926262
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.